These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25669762)

  • 1. Novel bioequivalence approach for narrow therapeutic index drugs.
    Yu LX; Jiang W; Zhang X; Lionberger R; Makhlouf F; Schuirmann DJ; Muldowney L; Chen ML; Davit B; Conner D; Woodcock J
    Clin Pharmacol Ther; 2015 Mar; 97(3):286-91. PubMed ID: 25669762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison Criterion.
    Jiang W; Makhlouf F; Schuirmann DJ; Zhang X; Zheng N; Conner D; Yu LX; Lionberger R
    AAPS J; 2015 Jul; 17(4):891-901. PubMed ID: 25840883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability and impact on design of bioequivalence studies.
    Van Peer A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multiple-dose safety and bioequivalence study of a narrow therapeutic index drug: a case for carbamazepine.
    Yacobi A; Zlotnick S; Colaizzi JL; Moros D; Masson E; Abolfathi Z; LeBel M; Mehta R; Golander Y; Levitt B
    Clin Pharmacol Ther; 1999 Apr; 65(4):389-94. PubMed ID: 10223775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-Based Bioequivalence Recommendations for Antiepileptic Drugs.
    Li Z; Fang L; Jiang W; Kim MJ; Zhao L
    Curr Neurol Neurosci Rep; 2017 Sep; 17(11):82. PubMed ID: 28929357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence approaches for highly variable drugs and drug products.
    Haidar SH; Davit B; Chen ML; Conner D; Lee L; Li QH; Lionberger R; Makhlouf F; Patel D; Schuirmann DJ; Yu LX
    Pharm Res; 2008 Jan; 25(1):237-41. PubMed ID: 17891552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of bioequivalence of psychotropic drugs and concerns involving product interchange.
    Barone JA; Byerly WG
    J Clin Psychiatry; 1986 Sep; 47 Suppl():28-32. PubMed ID: 2875067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An individual bioequivalence criterion: regulatory considerations.
    Chen ML; Patnaik R; Hauck WW; Schuirmann DJ; Hyslop T; Williams R
    Stat Med; 2000 Oct; 19(20):2821-42. PubMed ID: 11033578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing bioequivalence and drug interchangeability.
    Chen M; Chow SC
    J Biopharm Stat; 2017; 27(2):272-281. PubMed ID: 27936343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro bioequivalence testing.
    Chow SC; Shao J; Wang H
    Stat Med; 2003 Jan; 22(1):55-68. PubMed ID: 12486751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
    Karalis V; Symillides M; Macheras P
    Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating product bioequivalence for highly variable veterinary drugs.
    Claxton R; Cook J; Endrenyi L; Lucas A; Martinez MN; Sutton SC
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():11-6. PubMed ID: 22413787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence of generic lamotrigine 100-mg tablets in healthy Thai male volunteers: a randomized, single-dose, two-period, two-sequence crossover study.
    Srichaiya A; Longchoopol C; Oo-Puthinan S; Sayasathid J; Sripalakit P; Viyoch J
    Clin Ther; 2008 Oct; 30(10):1844-51. PubMed ID: 19014839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Exact Procedure for the Evaluation of Reference-Scaled Average Bioequivalence.
    Tothfalusi L; Endrenyi L
    AAPS J; 2016 Mar; 18(2):476-89. PubMed ID: 26831249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generic drug product equivalence: current status.
    Meyer MC
    Am J Manag Care; 1998 Aug; 4(8):1183-9; quiz 1190-2. PubMed ID: 10182892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual bioequivalence revisited.
    Chen ML; Lesko LJ
    Clin Pharmacokinet; 2001; 40(10):701-6. PubMed ID: 11707058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.